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Abstract
Background and Aim : Hepatitis C virus genotype 2 is the third
in order of frequency in Belgium. The aim of this study was to
 better define the genotype 2 carriers’ epidemiology characteristics.
Methods : In a database comprising 1726 viremic hepatitis C
virus patient from the south part of Belgium, the files of 98
 genotype 2 carriers were reviewed.
Results : There was a strong association between genotype 2 and
the mode of transmission. The rate of contamination by invasive
medical exams was very high (23%), and statistically different
from the one of the others genotypes. Eligibility for antiviral ther-
apies and the rate of sustained viral response were high.
Conclusion : HCV genotype 2 was highly associated with trans-
mission by invasive medical exams. (Acta gastro enterol. belg., 2011,
74, 277-280).
Key words : hepatitis C, genotype, nosocomial transmission, epidemi-
ology.
Introduction
Hepatitis C virus is a major public health problem
world-wide and the World Health Organization estimates
that 3% of the world population is infected with the hepa-
titis C virus (HCV). In Europe, 5 million people are HCV
carriers, the prevalence ranges from very low (< 0.1%) in
United Kingdom and Scandinavia, to low (0.1-0.5%) in
the rest of Western Europe and moderate (0.6%) in
Southern Europe (1). In a sample of the general popula-
tion in Belgium, the seroprevalence was 0.87% (2). 
More than 70% of newly infected patients progress to
chronic infection with its attendant complications of
 cirrhosis, liver failure and hepatocellular carcinoma (3).
Furthermore, the health-related quality of life is signifi-
cantly compromised in persons with chronic HCV, com-
pared with the general population (4).
HCV is classified into six major genotypes and
 several subtypes based on the nucleotide sequence
homology (5). Genotypes differ from each other by more
than 30% over the complete virus genome. These virus
types are each comprised of several more closely related
subtypes that vary by more than 20%, while within each
subtype variation is less than 10%. With longitudinal
studies that give a rate of substitution of 1.5 to 2 10-3 per
site per year, it was estimated that the divergence of
genotypes occurred at least 500-2000 years ago, whereas
thef divergence of subtypes has been proposed to derive
from 100 to 300 years (6).
Genotype identification is very important for different
reasons.
It is known that the prevalence and incidence of HCV
genotypes vary significantly among geographical
areas (7). Genotype 1 is distributed world-wide and is the
predominant genotype found in Europe and in the United
States, followed by genotypes 2 and 3. Genotype 4 is the
principal type in North and Central Africa and in the
Middle East. Genotypes 5 and 6 are rare, and are
 predominantly found in a specific geographical area :
genotype 5 is always a minor component of the HCV
population, except in South Africa or in some particular
areas ; and genotype 6 is mainly observed in South East
Asia (7). 
Genotype is the most important predictive factor of
response to therapy, and in many cases, determines the
duration of treatment (8).
In addition, a statistical association exists between
genotype and mode of transmission (9,10 and 11).
Genotype 3 and 1a are more frequent in younger patients
contaminated by intravenous drug use whereas genotype
1b and 2 are widely dominant among older patients with
a history of blood transfusion. Genotype 4 is described
in three different populations in the Southern part of
Belgium (patients of African origin, European drug users
and European non drug users, mostly of Italian  ori-
gin) (12). Genotype 5 is associated with patients contam-
inated by transfusion (13,14).
In addition to its role as an epidemiologic marker,
genotyping has thus an important role in the day-to-day
clinical management of chronic HCV infection, and its
prognosis. 
In spite of its importance in our populations, genotype
2 has not been very well studied. We aimed to better
determine the epidemiological characteristics and eligi-
bility to treatment of this subgroup of patients.
————————
Correspondence to : Virginie Putzeys, Rue Ferdinand Borny, 55, 4000 Liège,
Belgique. E-mail : Virginie.putzeys@chrcitadelle.be
Submission date : 26/07/2010
Acceptance date : 22/12/2010
Acta Gastro-Enterologica Belgica, Vol. LXXIV, April-June 2011
ORIGINAL ARTICLE 277
putzeys-:Opmaak 1  20/06/11  16:50  Pagina 277
278 V. Putzeys et al.
 history of medical invasive exam (23%), with 18 urolog-
ical interventions in the same unit (18%), six surgical
interventions (6%) and three contaminations to health
care workers, some of them with combined risk factors.
Seven patients were drug users (7%), and the mode of
transmission was unknown for 11 patients (sporadic
cases) (11%). There was no HIV co-infection. 
A liver biopsy was performed for 43 patients (82%) ;
a fibrosis score was known for 39 patients. Six had an
advanced fibrosis (Metavir score of F3-F4).
The treatment was described in 51 files. Thirty seven
patients (70.5%) were treated, either with pegylated
interferon or non pegylated interferon, often associated
with ribavirine. 68.5% patients developed a sustained
viral response (defined as undetectable viral load
6 months after the end of the treatment) (24 of the
35 patients who had a complete treatment and follow-
up). One patient was transplanted. From these
24 patients, 13 patients had a fibrosis score (Metavir) of
F0, 4 patients a fibrosis score of F1, 1 patient was F3,
three patients were F4 and the fibrosis score was not
determined in three patients.
Subtypes were very heterogeneous, but with a major-
ity of genotype 2a-2c : 68 patients had a genotype 2a-2c
(69%) ; 10 patients had a genotype 2a (10%) ;
14 patients had a genotype 2 (14%) ; one patient had a
genotype 2a-2c and 2b (1%) ; three patients had a geno-
type 2b (3%) ; one patient had a genotype 2a-2c and
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Material and methods
Study population
In a retrospective analysis from 1992 to 2002, 1726
consecutive patients were found HCV-RNA-positive by
polymerase chain reaction (PCR) in the Centre of
Molecular Diagnosis of University Hospital of Liege,
Belgium. These patients had been addressed to the teach-
ing hospital or nearby hospitals either to confirm the
diagnosis of hepatitis C by PCR or for a pre-treatment
evaluation. In this series, genotypes were known for
829 patients. Among them, 98 patients were infected
with genotype 2. A questionnaire was sent to the treating
physicians and their files were reviewed to collect infor-
mation about age, gender, ethnic origin, risk factors for
HCV acquisition, results of liver biopsy (Metavir score),
rate of patients eligible for therapy, rate of sustained viral
response when treated and rate of human immuno -
deficiency virus (HIV) co-infection. 
This study was approved by the Ethics Committee of
the University of Liege, Belgium.
Laboratory Methods
Qualitative HCV-RNA was assessed by nested PCR
between 1992 and 1995, by Amplicor HCV test (Roche
Laboratories, Basel, Switzerland), version 1.0 until 1998,
and then version 2.0). Genotypes were determined using
the LIPA-HCV test from Innogenetics (Zwijnaarde,
Belgium) and viral load by Amplicor HCV monitor test,
version 2.0 (Roche). All procedures were performed and
results interpreted according to the manufacturer’s
 recommendations.
Statistics
Continuous variables were analysed by Student’s
unpaired t-test. Categorical variables were tested by the
chi-square test, Mann-Withney test and Kologorv-
Smirnov test. Results were considered significant at the
classic level of 5%.
Results
Among the 829 patients with an identified genotype,
98 patients were infected with the genotype 2.
Genotype 1 was found among 510 patients (61.5%),
genotype 3 among 116 patients (14%), genotype 4
among 85 patients (10.3%), genotype 5 among
13 patients (1.6%) and genotype 6 among only two
patients (0.2%).
Characteristics of patients with genotype 2 (Table 1)
The mean age at the diagnosis was 48 +/- 15 years.
53 patients were female ; 45 were male. Mode of
 contamination was known for 88 patients. The main
mode of contamination was nosocomial : 31 patients had
received blood transfusion (31%), 23 patients had a
Table 1. — Clinical and epidemiological characteristics
of 98 patients with genotype 2
Characteristics n %
Age 48 +/- 15
Sex
Male 45 (46)
Female 53 (54)
Ethnic Group
African 16 (16)
European 82 (84)
Risk Factors 
Transfusion 31 (31)
Urological 18 (18)
Surgical 6 (6)
Health Care Workers 3 (3)
IV Drug Use 7 (7)
Unknown 21 (21)
Sexuel 1 (1)
Vertical 0
HIV co-infection 0
Hepatic biopsy n= 39
F0-F2 33 (85)
F3-F4 6 (15)
Treatment
Treated 37/51 (73)
Untreated 14/51 (27)
Transplantation 1 (6)
Viral response 25/37 (68)
Subtypes
2a-2c 68 (69)
2a 10 (10)
2 14 (14)
2a-2c and 2b/ ? 2 (2)
2b 3 (3)
2a-2b 1 (1)
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another unidentified subtype (1%) ; and one patient had
a genotype 2a-2b (1%).
Comparison of 98 genotype 2 carriers’ epidemiological
parameters with those of 1726 hepatitis C virus patients
Epidemiological parameters of 1726 hepatitis C virus
patients have been described previously (13) and are
reminded in the Table 2.
The characteristics of the 98 genotype 2 carriers did
not differ from those of the 1726 patients of the whole
series as far as age and gender were considered. Among
the genotype 2 carriers, however, there was a higher rate
of nosocomial contamination. The risk factor of contami -
nation by transfusion was higher among genotype 2 car-
riers. Moreover, medical invasive exams rate was signif-
icantly higher among genotype 2 carriers. Surgical trans-
mission was also found more often among genotype 2
carriers. The proportion of intravenous drug users was
less among genotype 2 carriers. There was no significant
difference for the others risk factors : sexual or vertical
transmission. There was no significant difference con-
cerning date of detection between the two series. 
Geographical distribution was also analysed, by using
the postal code. There was a significant difference, in the
province of Liege : in the city of Verviers, the prevalence
was higher (30%) than in the others cities of the province
(17%).
Nosocomial transmission was higher in genotype 2
carriers, especially for invasive medical exams.
Therefore, we analysed the characteristics of patients
infected with genotype 2 and contaminated by medical
invasive exams, versus patients with genotype 2 contam-
inated by other modes of contamination (Table 3). There
was no phylogenic analysis performed, but medical inva-
sive exams contamination were significantly associated
with subtype 2a-2c (p < 0.001), and with the city of
Verviers (p < 0.001). 
A multivariate analysis was performed for the mode
of contamination, to determine the main associated
 factor. This analysis confirmed that medical invasive
exams were significantly associated with genotype 2.
Discussion
Genotype 2 is the third most frequent genotype in our
countries (12%), after genotype 1 (61.5%) and genotype
3 (14%) (12). These data are similar to others studies for
infected patients in Benelux (12%) (15).
In our study, most of the patients were treated by an
association of nonpegylated interferon and ribavirine. A
high sustained viral response rate (67.5%) was found.
This rate was similar to the one of the literature for the
same regimen of treatment (usual in before) (16).
Moreover, eligibility for antiviral therapies was very
high (72.5%), which is much more than what was
described in our general HCV population (41%) (17).
This can be explained by the better results expected in
genotype 2 patients, in comparison with other genotype
carriers. The lower rate of drug users among genotype 2
patients may be another explanation.
This study showed the predominance of contamina-
tion with medical invasive exams (mainly urological
 procedures) in our population of genotype 2 infected
patients. This mode of contamination was suspected by
the hepatologist based on the typical medical history of
the patient and the exclusion of other modes of trans -
mission. This is an illustration of the persistence of
 iatrogenic transmission of the virus C during the last
twenty years, as demonstrated by several publication
elsewhere (18-28). Concerning the transmission by
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Table 2. — Comparison of 98 genotype 2 carriers’
epidemiological parameters with
those of 1726 hepatitis c virus patients
Characteristics Genotype 2 Patients HCV P
n = 98 n = 1726
Age 48 +/- 15 47 +/-17 NS
Sex
Male 45 (47%) 917 (53%) NS
Female 53 (53%) 808 (47%) NS
Risk factors 
Transfusion 31 (31%) 399 (23%) = 0,05
Medical invasive exams 23 (23%) 97 (5,6%) < 0,001
Surgical 6.1 (6%) 9 (0.52%) < 0,001
Dialysis 0 32 (1,9%) NS
Sexual 1 (1%) 20 (1%) NS
Vertical 0 4 (0,23%) NS
IV Drug Use 7 (7%) 254 (14%) < 0,05
Date of Detection 1998 +/- 3 1998 +/- 3
Locality
4000 16 (17%) 455 (28%) < 0,05
4800 28 (30%) 260 (16%) < 0,05
Table 3. — Genotype 2 carriers’ infected by medical
invasive exams : epidemiological characteristics
Parameters EMI Others G2 P
n = 23 n = 75
Age 49 48
Sex
Male 9 36 NS
Female 14 39 NS
Liver Biopsy 14/15 29/37 NS
F0-F2 11/12 22/27 NS
F3-F4 1/12 5/27 NS
Treatment
Treated 13/15 24/36 NS
Untreated 2/15 12/36 NS
SVR 7/10 17/25 NS
Subtypes
2a 3 7 NS
2a-2c 20 47 < 0,001
Others 21 < 0,01
Locality
Verviers 18 15
Liège and around 5 58 < 0,001
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 urological procedures in our study, it seems that the
 contamination were related to the use of the same
 contrast medium vial for several patients during the
 realisation of intravenous pyelography (the short catheter
connected with the vial, and changed after each
 procedure, being too short to avoid blood flow reflux in
the vial). In fact, some patients developed acute hepati-
tis C a few weeks after this procedure. By this way, the
responsibility of this technique was suspected. A few
years later, patients were seen with chronic hepatitis C,
medical history of urological procedure, and no other
risk factors. The reason why the contamination occurred
mainly with genotype 2 remains indeterminate. De
Ledinghen described in 2005 a similar situation : patients
were contaminated during sclerotherapy of varicose
veins by a same physician who used a single vial for
multiples patients (29-30). Whether the genotype 2 could
resist longer than other genotype is a question that could
be raised, but without having found concluding argu-
ments in the literature. 
The main message of this study is that poor infection
control techniques in some subregions can have a
 sufficient magnitude to change significantly a whole
population epidemiology.
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